Clearmind (CSE: CMND) (FSE: CWY0) Management invites leaders, innovators, scientists, doctors, patients, enthusiasts, and luminaries in the psychedelic space to attend a virtual Q&A session on March 30th, focused on the potential treatment of alcohol use and binge drinking based on its psychoactive molecule MEAI.
Global leaders and innovators in the psychedelic space will participate in the virtual event and discuss psychedelic therapies and treatments for excessive alcohol consumption and mental disorders. The dedicated team of experts at Clearmind is engaged in developing breakthrough treatments for binge behaviour, alcohol use disorder, binge eating and depression.
Adi Zuloff-Shani, PhD, Clearmind’s Chief Executive Officer, is one of the leading speakers at the event, with over 20 years of strategic and operational leadership in the health care industry and in-depth knowledge on therapeutics development in heavily regulated environments. In addition, Shannon Smadella, Clearmind’s Community Development, will host the Q&A sessions. She has interviewed numerous innovators, doctors and luminaries in the health and wellness space.
Adjunct Prof. Mark Haden, Clearmind’s VP of Business Development, is also one of the speakers at the Clearmind Mangement event. Mark has published on the issue of drug control policy and psychedelics and has significant contribution in counselling, supervisory and management of addiction.
Previously, people needing care for alcohol use disorders had only a limited range of options. At the Clearmind Management Psychedelics for Alcoholism session, influential personas and leading doctors, scientists, and professors of the psychedelic space will discuss the drug control policies, as well as offer counselling and advice on addiction, binge eating and depression.
The agenda of the event is to create awareness about the potential treatment for alcohol use disorder, psychedelics and other therapies, and make them more acceptable. This event will offer a robust platform for discussions among renowned leaders about the psychedelic treatment options for binge drinking, and further, how these medicines enhance the mental state.
The Clearmind Management panel will answer queries on alcohol use disorder, and eminent industry thinkers who have spent years researching the phenomenal uses of psychedelic compounds will offer their valuable opinions about the treatment of alcohol use disorder using its psychoactive molecule MEAI.
Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the “Company“), a psychedelic medicine biotech company engaged in the discovery and development of novel psychedelic-derived therapeutics, recently announced its entry into a development and supply agreement with Aragen Life Sciences Pvt. Ltd (“Aragen”) for the production of its innovative molecule, 5-Methoxy-2-aminoindane (“MEAI”) (https://ibn.fm/WkwwD).
For more information, please visit https://ibn.fm/BLHsB
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment